drugset / Trial / NCT00596245

Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets

NCT00596245

Phase 1 Completed 42 enrolled GlaxoSmithKline POZEN · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

This is an open-label, parallel group, single-center study. The study design consists of a screening and a treatment period. A total of 42 (approximately 21 of each sex) non-smoking healthy volunteers aged 18 - 35.

Timeline

Start
2007-10
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MT400 Unknown
Subject Naproxen Small molecule 550 mg

Indications

No indication recorded.